Trastuzumab Deruxtecan Breast Cancer Survival HER2-Low

Okay, this is a vrey extensive list of financial disclosures.Here’s a breakdown,⁢ categorized for⁣ clarity.‍ I’ll try to ⁤make it as readable as possible, focusing on the types ⁢of relationships and the companies involved.This is a⁢ long response, reflecting the⁣ complexity of the ⁢original text.

Crucial Note: This is a summary. The original text should be consulted for complete and precise details. “Received” is used as a general term encompassing grants,honoraria,consulting ⁤fees,etc., unless specifically stated.

I. Individual Disclosures (Alphabetical by Initials)

* ⁢ A.P.

⁤ * Grants: Daiichi Sankyo, AstraZeneca, Boehringer, Novartis, Roche, Pfizer, Lilly, Reveal Genomics
* Consulting Fees: Daiichi Sankyo, AstraZeneca, Roche, Pfizer, Novartis, Puma, Peptomyc, Reveal Genomics, Ona Therapeutics
* Honoraria: Daiichi Sankyo, Roche, Pfizer, Novartis
⁤ * Patents: ⁢CES WO/2018/096191,⁤ ERBB2 WO2018/103834A1 (issued), DNADX (pending), HER2DX‍ (pending), TNBCDX (pending)
* Leadership/Fiduciary Roles: Reveal Genomics (leadership/fiduciary role, board of directors)
⁢ * Stock/Options: Reveal Genomics, Ona Therapeutics

* ⁣ H.S.R.

* ‍ Grants: Daiichi ⁤sankyo, AstraZeneca, F. Hoffmann-La Roche Genentech,Gilead Sciences,Lilly,Merck,Novartis,Pfizer,Pionyr⁢ Immunotherapeutics,Sermonix Pharmaceuticals,Stemline Therapeutics,OBI Pharma
* Consulting Fees: daiichi Sankyo,Mylan,Viatris,NAPO,Puma

* K.P.

* Grants: Daiichi sankyo, ⁢AstraZeneca, Merck, Novartis, Primeview, GSK, BMS,‍ Boehringer Ingelheim,⁣ IQVIA, health Data Specialists ⁣AE, MSD, Roche, PPD, ⁤Lilly, Gilead, Genesis, Sanofi,⁤ Value Research AE
* consulting⁤ Fees: Novartis, Gilead, MSD, Lilly, primeview
* Honoraria: AstraZeneca, MSD, Novartis, Roche, Gilead, Ipsen,⁣ Lilly, Pharmabide, Genesis
* ⁣ Travel/Meeting Support: AstraZeneca, DEMO, MSD, Novartis, Roche, Gilead, Genesis

* K.Z.

* Grants: Roche
* Honoraria: Daiichi Sankyo, AstraZeneca, MSD, Exact Sciences, Lilly, Pierre Fabre, gilead,⁢ Novartis, Pfizer, Roche, Seagen
* ‍ Travel/Meeting Support: Daiichi Sankyo, AstraZeneca, Gilead, Pfizer,‍ Pierre fabre, Roche
⁤ * Advisory/Monitoring Boards: Daiichi Sankyo, AstraZeneca, Exact Sciences, Gilead, Novartis, Lilly, MSD, Pierre Fabre,⁣ Seagen
⁢ * Steering Committee: Daiichi ⁤Sankyo, Pierre Fabre (international trial)
⁤ * Data Monitoring Committee: ⁣Roche (international trial)

* N.H.

⁤ * Consulting Fees: Gilead, roche, sandoz, Sanofi, Seagen
⁢ ⁤* Honoraria: daiichi Sankyo, AstraZeneca, Amgen, EPG Communication, Gilead, Lilly, MEDSCAPE, MSD, Novartis, Pierre Fabre, Pfizer, ⁤Roche, Sanofi, Seagen, Springer, Viatris, Zuelligpharma
* Advisory/Monitoring Boards: roche
* Leadership/Fiduciary Roles: West German‍ Study Group

* T.Y.

⁣ ⁢* Grants: Daiichi Sankyo, AstraZeneca, Chugai, Taiho, Nippon Kayaku, Eli Lilly, Pfizer, Seagen, MSD, Kyowa Kirin
* Honoraria: Daiichi Sankyo, AstraZeneca, Chugai, Eisai, Novartis Pharma, Taiho, Nippon Kayaku, Kyowa Kirin, Pfizer, Eli Lilly

II. Collective/Group Disclosures (Companies Mentioned)

This section lists all companies mentioned across‍ all individual disclosures.It’s useful for a swift overview of the breadth ‍of relationships.

* AstraZeneca: Extremely frequent⁣ – grants, consulting, honoraria, travel support, advisory boards, steering committees.
* Daiichi Sankyo: extremely frequent ‍- grants, consulting, honoraria, travel support, advisory boards, steering ⁢committees.
* Roche/Genentech: Very frequent – grants,